NetworkNewsBreaks – Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) Reports Positive Top Line Phase 2 Data of INOpulse® to Treat PH-COPD
Bellerophon Therapeutics (NASDAQ: BLPH) this morning reported positive top line data from its phase 2 clinical trial evaluating INOpulse® in patients with Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease (PH-COPD). The phase 2 study was designed to measure the acute effect of pulsed inhaled nitric oxide (iNO) on targeted vasodilation, as well as the chronic effect (4 weeks) of iNO on hemodynamics and exercise capacity. The acute effect results show statistically significant increases in blood vessel volume on iNO compared to baseline. Additionally, the chronic results demonstrated statistically significant and clinically meaningful increases in six-minute walking distance compared to…







